AvenCell Therapeutics, Inc

General information
AvenCell Therapeutics, Inc
500 Forge Road
02472 Watertown, Massachusetts
USA

Contact person: Andrew Schiermeier, Chief Executive Officer
Company main phone: +1 (617) 9417468
Website:  https://avencell.com
Year founded:2021
Source of foundation:Independent foundation
Corporate description / mission:
AvenCell Therapeutics, Inc., a clinical-stage cell therapy company. The company's mission is to overcome the limitations of current-generation CAR-T cell therapies with an improved therapeutic window and substantially expand the types of cancer treatable with adoptive cell therapy, including solid tumors.
State of ownership: Private / independent
Headquarters: HQ: Yes
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Cell therapy
  • Immunotherapy
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • R&D
Customer segments:
  • Other
  • Hospitals
  • Large biotech & big pharma
  • Small biotech
Distribution:
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:4
Phase II:2
Description of products:
AVC-201
AVC-202
AVC-203 etc.
Technology used:
UniCAR, RevCAR and TCE
Collaborations & Clients
Partnering strategy / collaborations:
Intellia Therapeutics
Blackstone Lifesciences
© 2025 Biotechgate by Venture Valuation
X